Please login to the form below

Not currently logged in
Email:
Password:

NICE recommendation

This page shows the latest NICE recommendation news and features for those working in and with pharma, biotech and healthcare.

NICE backs EUSA's RCC treatment Fotivda

NICE backs EUSA's RCC treatment Fotivda

NICE backs EUSA's RCC treatment Fotivda. The UK’s cost-effectiveness watchdog recommends its first-line use. ... Fotivda has the potential to become an important new first-line therapy and the recommendation by NICE is a great achievement for the EUSA

Latest news

  • Novartis’ Extavia evades NICE restrictions on MS drugs Novartis’ Extavia evades NICE restrictions on MS drugs

    Novartis’ Extavia evades NICE restrictions on MS drugs. But Avonex, Plegridy, Betaferon, Rebif and Copaxone are set to be turned down. ... The MS Society is trying to mobilise patients and healthcare professionals to respond to the proposals and urge

  • NICE backs Pfizer’s Xeljanz for RA NICE backs Pfizer’s Xeljanz for RA

    Pfizer is celebrating a positive recommendation from the National Institute for Health and Care Excellence (NICE) for Xeljanz (tofacitinib citrate), a new treatment option for patients with a severe, active form ... alone. Mason added: “We are

  • NICE expands Merck KGaA’s Erbitux reach NICE expands Merck KGaA’s Erbitux reach

    NICE expands Merck KGaA’ s Erbitux reach. Backs the medicines use for patients with SCCHN. ... access to Erbitux and that NICE has recognised the survival benefit it can offer to patients with this disease.”.

  • NICE backs Cancer Drugs Fund support for Roche's Gazyvaro NICE backs Cancer Drugs Fund support for Roche's Gazyvaro

    CDF). The recommendation delivered by NICE this morning means that Gazyvaro (obinutuzumab) can be used in combination with chemotherapy to treat patients with follicular lymphoma that has not responded to treatment ... NICE cleared Gazyvaro as a routine

  • NICE green lights Keytruda for second-line lung cancer NICE green lights Keytruda for second-line lung cancer

    It is the first checkpoint inhibitor to be approved by NICE for this use. ... of patients, so the NICE recommendation for pembrolizumab is great news.

More from news
Approximately 2 fully matching, plus 125 partially matching documents found.

Latest Intelligence

  • Positive disruption in business intelligence Positive disruption in business intelligence

    Take the recent recommendation by NICE, the UK’s drug-spending policymaker, of Kadcyla, the breast cancer treatment launched by Roche. ... In December 2016, NICE issued draft guidance indicating Kadcyla was too expensive for routine funding on the NHS.

  • Rare diseases: meeting the challenge Rare diseases: meeting the challenge

    Companies will still need to work hard to win a NICE ‘yes’recommendation, and may still yet have to accept optimised - as NICE calls them - or restricted - as industry calls them - ... None of the four therapies approved to date under the NICE HST

  • The death of the cancer drugs fund? The death of the cancer drugs fund?

    evidence to support a recommendation for routine commissioning, and where additional evidence would be likely to enable a more informed NICE appraisal decision. “ ... positive recommendation at which point it would move out of the Fund into mainstream

  • Transforming times at AstraZeneca Transforming times at AstraZeneca

    She gives the example of a drug to prevent a second heart attack that has a positive NICE recommendation, can save people's lives and reduce further hospital costs. “ ... It sounds like good value and NICE has also said it is,” says Anson. “

  • Creating a 21st century life sciences ecosystem Creating a 21st century life sciences ecosystem

    England's health technology assessor NICE, which decides which drugs the NHS should pay for. “ ... So, where you do get a licensing approval, then a NICE recommendation, there isn't such a long delay to get uptake.".

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Kantar Health

Kantar Health is a leading global healthcare consulting firm and trusted advisor to many of the world’s leading pharmaceutical, biotech,...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics